INCB 54828

Drug Profile

INCB 54828

Alternative Names: INCB 054828; INCB54828

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Incyte Corporation
  • Class Antineoplastics
  • Mechanism of Action Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Lymphoid leukaemia; Myeloid leukaemia; Myeloproliferative disorders; Urogenital cancer
  • Phase I/II Cancer; Multiple myeloma
  • Phase I Solid tumours

Most Recent Events

  • 03 Aug 2017 Incyte Corporation plans a phase I trial for Solid tumours(Late-stage disease) in Japan (NCT03235570)
  • 01 Aug 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease) in Japan (unspecified route) (NCT03235570)
  • 22 Jun 2017 Pharmacodynamics data from a single patient from phase I/II trial in Cancer presented at the 22nd Congress of the European Haematology Association (EHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top